Tesofensine

Cognitive · Triple reuptake inhibitor

Tier C-

investigational

4.2 / 10

Tier C-

Ev 3.0 Bn 6.5 Sf 3.5 Ax 5.0

What this is

Saniona now developing for hypothalamic obesity (rare disease orphan indication). Substantial weight loss in obesity trials. Cognitive trials disappointed. Research chem availability exists; caution with CV effects.

Mechanism

Inhibits DAT, NET, SERT; originally developed by NeuroSearch for Alzheimer's/Parkinson's (failed primary endpoints); repurposed for obesity with striking weight loss effects

Dose & route

0.25-1 mg/day PO in obesity trials

Citations

https://pubmed.ncbi.nlm.nih.gov/18206399/
https://pubmed.ncbi.nlm.nih.gov/18842805/
https://pmc.ncbi.nlm.nih.gov/articles/PMC9269579/

Links go to the source. If a link is dead or you want something re-checked, let me know.

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.